Read by QxMD icon Read

Metformin in pcos

Zheying Min, Qian Gao, Xiumei Zhen, Yong Fan, Tao Tan, Rong Li, Yue Zhao, Yang Yu
BACKGROUND: Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder that affects female fertility. However, with the lack of a corresponding research model, the pathology mechanism of PCOS is poorly understood. Induced pluripotent stem cell (iPSC) technology has been recognized as means to generate patient-specific stem cells for disease modeling. METHODS: The mRNA abundance of iPSCs was analyzed by RNA microarray and real-time polymerase chain reaction (RT-PCR)...
August 9, 2018: Stem Cell Research & Therapy
Ewa Otto-Buczkowska, Karolina Grzyb, Natalia Jainta
Polycystic ovary syndrome (PCOS) usually arises during puberty and is marked by insulin resistance, hyperinsulinemia, and hyperandrogenism. The principle is that the diagnosis of PCOS must be based on the presence of at least two of the following three criteria: chronic anovulation, hyperandrogenism (clinical or biological), and polycystic ovaries. The diagnosis of PCOS in adolescents is particularly difficult due to developmental problems in this group. Many symptoms of PCOS, including acne, menstrual irregularities, and hyperinsulinemia, are common in normal puberty...
2018: Pediatric Endocrinology, Diabetes, and Metabolism
F-F Wang, Y Wu, Y-H Zhu, T Ding, R L Batterham, F Qu, P J Hardiman
BACKGROUND: Women with polycystic ovary syndrome (PCOS) are almost three times more likely to be obese than those without PCOS. However, we have no specific interventions to induce weight loss so far and rely on drugs used to treat other symptoms of the syndrome or obesity in the general population. OBJECTIVE: The objective of this study is to compare the effectiveness of metformin, inositol, liraglutide and orlistat to induce weight loss in women with PCOS and overweight/obesity...
July 31, 2018: Obesity Reviews: An Official Journal of the International Association for the Study of Obesity
Christos Dragamestianos, Christina I Messini, Pantelis T Antonakis, Konstantina Zacharouli, Evanthia Kostopoulou, Antonis Makrigiannakis, Panagiotis Georgoulias, George Anifandis, Konstantinos Dafopoulos, Antonios Garas, Alexandros Daponte, Ioannis E Messinis
OBJECTIVES: To investigate the effect of metformin on endometrial receptivity in women with polycystic ovary syndrome (PCOS). METHODS: Twenty volunteer women with polycystic ovaries and oligomenorrhea were prospectively investigated. All women were treated with exogenous estradiol and progesterone to simulate a normal menstrual cycle (28-day duration) after GnRH-induced pituitary desensitization. Ten of the women received no other medication (group A, control), while the remaining 10 received metformin (group B, metformin)...
July 26, 2018: Gynecologic and Obstetric Investigation
Emaduldin Seyam, Enas Hefzy
The aim of the current work was to investigate the value of the long term effects of combined use of simvastatin and metformin treatment for a year versus the effects of their individual treatment on the clinical, biochemical abnormalities, and ovulation dysfunction in young single women with polycystic ovary syndrome (PCOS). It was a randomized, double-blind controlled study. Where two hundreds (n = 200) single young women with PCOS were randomized into seventy (n = 70) women using simvastatin 20 mg daily combined with metformin 500 mg three times daily considered as group A (study group), and another 2 sixty five (n = 65) women groups using simvastatin and metformin individually as a single treatment use, and considered as groups (B & C), respectively...
July 25, 2018: Gynecological Endocrinology
Jodie M Dodd, Rosalie M Grivell, Andrea R Deussen, William M Hague
BACKGROUND: There has been considerable interest in providing antenatal dietary and lifestyle advice for women with obesity or who are overweight during pregnancy, as a strategy to limit gestational weight gain and improve maternal and infant health. However, such antenatal interventions appear to have a modest effect on gestational weight gain and other clinical pregnancy and birth outcomes and additional strategies are required.Metformin is an oral insulin-sensitising medication that acts to decrease blood glucose concentrations...
July 24, 2018: Cochrane Database of Systematic Reviews
Stephan Scherneck, Natalie Schlinke, Evelin Beck, Katharina Grupe, Corinna Weber-Schoendorfer, Christof Schaefer
The aim of this study was to evaluate the risk of major birth defects and spontaneous abortion after metformin use during the first trimester of pregnancy. We conducted an observational cohort study comparing pregnancies with metformin treatment during the first trimester with non-exposed women matched for BMI and year of enrolment. Pregnancies were prospectively ascertained in the German Embryotox pharmacovigilance database between 2004 and 2014. The study sample included 336 pregnancies with metformin exposure for PCOS and fertility disorders (56...
July 11, 2018: Reproductive Toxicology
Steve Hyer, Jyoti Balani, Hassan Shehata
Metformin use in pregnancy is increasing worldwide as randomised controlled trial (RCT) evidence is emerging demonstrating its safety and efficacy. The Metformin in Gestational Diabetes (MiG) RCT changed practice in many countries demonstrating that metformin had similar pregnancy outcomes to insulin therapy with less maternal weight gain and a high degree of patient acceptability. A multicentre RCT is currently assessing the addition of metformin to insulin in pregnant women with type 2 diabetes. RCT evidence is also available for the use of metformin in pregnancy for women with Polycystic Ovarian Syndrome and for nondiabetic women with obesity...
July 4, 2018: International Journal of Molecular Sciences
Linda A Barbour, Christina Scifres, Amy M Valent, Jacob E Friedman, Thomas Buchanan, Donald Coustan, Kjersti Aagaard, Kent L Thornburg, Patrick M Catalano, Henry Galan, William W Hay, Antonio E Frias, Kartik Shankar, Rebecca A Simmons, Robert G Moses, David A Sacks, Mary R Loeken
Use of oral agents to treat gestational diabetes mellitus (GDM) remains controversial. Recent recommendations from the Society for Maternal Fetal Medicine (SMFM) assert that metformin may be a safe first line alternative to insulin for GDM treatment and preferable to glyburide. However, several issues should give pause to the widespread adoption of metformin use during pregnancy. Fetal concentrations of metformin are equal to maternal, and metformin can inhibit growth, suppress mitochondrial respiration, have epigenetic modifications on gene expression, mimic fetal nutrient restriction, and alter postnatal gluconeogenic responses...
June 27, 2018: American Journal of Obstetrics and Gynecology
Selenay Furat Rencber, Sema Kurnaz Ozbek, Ceyla Eraldemır, Zehra Sezer, Tugba Kum, Sureyya Ceylan, Elif Guzel
BACKGROUND: PCOS is a reproductive hormonal abnormality and a metabolic disorder. It is frequently associated with insulin resistance, hyperandrogenism, chronic inflammation, and oxidative stress. We aim to investigate the potential therapeutic effects of combined therapy of resveratrol and metformin on polycystic ovaries via SIRT1 and AMPK activation. METHODS: Wistar albino rats were divided into control and experimental (PCOS) groups. DHEA-induced PCOS rats were given resveratrol (20 mg/kg/day), metformin (300 mg/kg/day) and combined therapy...
June 29, 2018: Journal of Ovarian Research
Sima Taghvaee Javanshir, Parichehreh Yaghmaei, Zahra Hajebrahimi
Background: Polycystic ovary syndrome (PCOS) is a common form of the endocrine disease which is associated with metabolic dysfunction. PCOS and type 2 diabetes mellitus are related in multiple aspects and are similar in many pathological features. Anti-diabetic effects of Nigella sativa and protective effects of it on reproductive system have been suggested in some reports. Objective: The aim of current study was to evaluate the effects of thymoquinone, the main components of Nigella sativa , on PCOS model of rats...
April 2018: International Journal of Reproductive Biomedicine (Yazd, Iran)
Liv Guro Engen Hanem, Rønnaug Ødegård, Eszter Vanky
No abstract text is available yet for this article.
June 20, 2018: Journal of Clinical Endocrinology and Metabolism
Carolina Castillo-Castro, Camilo Gonzalez-Velazquez, Rene Rodriguez-Gutierrez
No abstract text is available yet for this article.
June 20, 2018: Journal of Clinical Endocrinology and Metabolism
Jing Zhao, Xiaoyan Liu, Wenhua Zhang
OBJECTIVE: This study was to analyze the efficacy of metformin intervention in preventing gestational diabetes mellitus (GDM). METHODS: A systematic review and meta-analysis of clinical trials or observational studies of metformin intervention in preventing symptoms of GDM during pregnancy were performed. Medline, Embase, and Cochrane Library were searched through to now. The main evaluated primary outcomes were incident of GDM, miscarriage, preterm delivery, and neonatal mortality...
June 11, 2018: Experimental and Clinical Endocrinology & Diabetes
Tom Tanbo, Jan Mellembakken, Sverre Bjercke, Eva Ring, Thomas Åbyholm, Peter Fedorcsak
The objective of this narrative review was to suggest a rational order of treatment choices in anovulatory women with polycystic ovary syndrome (PCOS), for whom a multitude of treatment options exist. In obese/overweight women with PCOS the importance of weight reduction should be stressed. Inositol, a dietary supplement with a documented effect on ovulation and without adverse effects in the doses recommended, may be suggested. Additional first-line medical alternatives include insulin sensitizers, selective estrogen receptor modulators, and aromatase inhibitors...
June 11, 2018: Acta Obstetricia et Gynecologica Scandinavica
Mohammad Reza Dorvash, Mohammad Javad Khoshnood, Hossein Saber, Amirreza Dehghanian, Pouria Mosaddeghi, Negar Firouzabadi
Gallstone disease (GD) is highly correlated with metabolic syndrome and its related illnesses including type II diabetes (DMII) and polycystic ovary syndrome (PCOS). While previous studies claimed that metformin decreases the chance of developing GD in PCOS patients, this phenomenon has not been investigated in animal models to date. Here we fed a high fat diet (HFD) containing 2% of cholesterol and 1% of cholic acid to ten-week-old male C57Bl/6 mice for 105 days. The groups were as follows: Low fat diet; HFD; HFD + Ursodeoxycholic acid (UDCA) (day 1-105); HFD + Metformin (day 1-105); HFD + Metformin (Met) (day 64-105)...
August 15, 2018: European Journal of Pharmacology
Serkan Bodur, Ozgur Dundar, Mine Kanat-Pektas, Mehmet Ferdi Kinci, Levent Tutuncu
OBJECTIVE: This study was designed to evaluate the effects of 3 mg drospirenone/30 μg ethinyl estradiol (OC) alone or combined with 1700 mg metformin on metabolic risk factors. MATERIALS AND METHODS: In this randomized, prospective, controlled study, 87 non-obese (18-30 BMI) women of reproductive age (18-39) with polycystic ovary syndrome (PCOS) were assigned to control (n = 17), OC (n = 21), combination (n = 20) and metformin (n = 29) therapy groups...
June 2018: Taiwanese Journal of Obstetrics & Gynecology
Chau T Tay, Anju E Joham, Danielle S Hiam, Moustafa A Gadalla, Jyotsna Pundir, Shakila Thangaratinam, Helena J Teede, Lisa J Moran
BACKGROUND: Polycystic ovary syndrome (PCOS) affects up to 13% women and is associated with significant complications. The quality of evidence supporting the recommendations on treatment of nonreproductive outcomes in PCOS is unknown. OBJECTIVE: To summarize and appraise the methodological quality of systematic reviews and meta-analyses evaluating pharmacological and surgical treatments for nonreproductive outcomes in PCOS. METHODS: A literature search from MEDLINE, EMBASE, CINAHL PLUS and PROSPERO was performed from inception until 15th of September 2017...
May 30, 2018: Clinical Endocrinology
Vesna Salamun, Mojca Jensterle, Andrej Janez, Eda Vrtacnik Bokal
OBJECTIVE: Glucagon-like peptide-1 (GLP-1) has been investigated in regulation of reproductive system in animal models. The potential impact of short-term preconception intervention with liraglutide on fertility potential in polycystic ovary syndrome (PCOS) has not been evaluated yet. DESIGN: A prospective randomized open-label study was conducted in 28 infertile obese PCOS patients (age: 31.07 ± 4.75, BMI: 36.7 ± 3.5 kg/m2 , mean ± s.d.). They were assigned to metformin (MET) 1000 mg BID or to MET 1000 mg BID combined with low-dose liraglutide 1...
July 2018: European Journal of Endocrinology
Seema Patel
Polycystic ovary syndrome (PCOS) is an endocrine disorder, afflicting females of reproductive age. This syndrome leads to infertility, insulin resistance, obesity, and cardiovascular problems, including a litany of other health issues. PCOS is a polygenic, polyfactorial, systemic, inflammatory, dysregulated steroid state, autoimmune disease, manifesting largely due to lifestyle errors. The advent of biochemical tests and ultrasound scanning has enabled the detection of PCOS in the affected females. Subsequently, a huge amount of insight on PCOS has been garnered in recent times...
September 2018: Journal of Steroid Biochemistry and Molecular Biology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"